Fosaprepitant Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-421

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Fosaprepitant (NDC 68001-421). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fosaprepitant For Injection 150 mg Carton Label (Ctn150mg)

Fosaprepitant For Injection 150 mg Carton Label (Ctn150mg)
This is a description of a medicine product called Fosaprepitant and its packaging. The package contains a single-dose vial of sterile lyophilized powder for intravenous use. The vial should be reconstituted with 5 mL of 0.9% Sodium Chloride for Injection. The medicine is to be used only after reconstitution and dilution. The usual dosage should be followed as per prescribing information. The inactive ingredients in the medicine are edetate disodium, polysorbate 80, lactose anhydrous, sodium hydroxide and/or hydrochloric acid for pH adjustment. The vial must be refrigerated between 2°C to 8°C. The reconstituted drug solution is stable for 24 hours at ambient room temperature at or below 25°C. The package also contains details about the manufacturer and the batch number. A 2D barcode is printed for batch details.*
FDA Label Image

Fosaprepitant For Injection 150 mg Vial Label (Lbl150mg)

Fosaprepitant For Injection 150 mg Vial Label (Lbl150mg)
FDA Label Image

Structure-01 (Structure 01)

Structure-01 (Structure 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.